"Designing Growth Strategies is in our DNA"

U.S. Vaginal Atrophy Treatment Market Size, Share & Industry Analysis, By Therapy Type (Drug Therapies {Estrogen Based [Imvexxy, Premarin, and Others], Non-Estrogen Based [Intrarosa and Osphena]}), Non Drug Therapies {(Hyaluronic-Acid (HA) Based OTC Solutions [HA Vaginal Suppositories/Inserts, HA Gels & Creams, Others], Others OTC Moisturizers & Lubricants, Light Therapy, Lasers, and Others}), By Route of Administration (Oral, Parenteral, and Topical {Vaginal Inserts / Suppositories, Gels & Creams, & Others}) By Distribution Channel, and Country Forecast, 2026-2034

Last Updated: January 19, 2026 | Format: PDF | Report ID: FBI109727

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Pipeline Analysis, By Key Players
    2. New Product Launches, By Key Players
    3. Prevalence of Vaginal Atrophy, U.S.
    4. Key Industry Developments, By Key Players
    5. Insights Related to Non-Drug Therapies:
      1. Regulatory Scenario for Non-Drug Therapies in the U.S.
      2. Consumer Preference Patterns
      3. Pricing Analysis of Key Brands
      4. New Product Launches, By Key Players
  5. U.S. Vaginal Atrophy Treatment Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Therapy Type
      1. Drug Therapies
        1. Estrogen Based
          1. Imvexxy
          2. Premarin
          3. Others
        2. Non-Estrogen Based
          1. Intrarosa
          2. Osphena
      2. Non Drug Therapies
        1. Hyaluronic-Acid (HA) Based OTC Solutions
          1. HA Vaginal Suppositories/Inserts
            1. HA Gels & Creams
            2. Others
          2. Other OTC Moisturizers & Lubricants
            1. Polycarbophil-based Moisturizers
            2. Water-based Lubricants
            3. Others
          3. Light Therapy
          4. Lasers
          5. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
      3. Topical
        1. Vaginal Inserts / Suppositories
        2. Gels & Creams
        3. Serums / Oils
        4. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Store & Pharmacies
      3. Mass Merchandisers
      4. E-Commerce & Digital Platforms
      5. Others
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2024)
    2. Drug Therapies - Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
      1. Pfizer Inc.
      2. Mayne Pharma Group Limited
      3. Duchesnay USA
      4. Church & Dwight Co., Inc.
      5. Pharmavite LLC
      6. Novartis AG
      7. Novo Nordisk A/S
      8. Millicent Pharma Ltd.
      9. Besins Healthcare
      10. Good Clean Love
      11. Laclede, Inc.
      12. Femallay Inc.
      13. Fidia Farmaceutici S.p.A.
      14. Joylux, Inc.
      15. Combe
      16. Reckitt
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Pipeline Analysis, By Key Players
    2. New Product Launches, By Key Players
    3. Prevalence of Vaginal Atrophy, U.S.
    4. Key Industry Developments, By Key Players
    5. Insights Related to Non-Drug Therapies:
      1. Regulatory Scenario for Non-Drug Therapies in the U.S.
      2. Consumer Preference Patterns
      3. Pricing Analysis of Key Brands
      4. New Product Launches, By Key Players
  5. U.S. Vaginal Atrophy Treatment Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Therapy Type
      1. Drug Therapies
        1. Estrogen Based
          1. Imvexxy
          2. Premarin
          3. Others
        2. Non-Estrogen Based
          1. Intrarosa
          2. Osphena
      2. Non Drug Therapies
        1. Hyaluronic-Acid (HA) Based OTC Solutions
          1. HA Vaginal Suppositories/Inserts
            1. HA Gels & Creams
            2. Others
          2. Other OTC Moisturizers & Lubricants
            1. Polycarbophil-based Moisturizers
            2. Water-based Lubricants
            3. Others
          3. Light Therapy
          4. Lasers
          5. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
      3. Topical
        1. Vaginal Inserts / Suppositories
        2. Gels & Creams
        3. Serums / Oils
        4. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Store & Pharmacies
      3. Mass Merchandisers
      4. E-Commerce & Digital Platforms
      5. Others
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2024)
    2. Drug Therapies - Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
      1. Pfizer Inc.
      2. Mayne Pharma Group Limited
      3. Duchesnay USA
      4. Church & Dwight Co., Inc.
      5. Pharmavite LLC
      6. Novartis AG
      7. Novo Nordisk A/S
      8. Millicent Pharma Ltd.
      9. Besins Healthcare
      10. Good Clean Love
      11. Laclede, Inc.
      12. Femallay Inc.
      13. Fidia Farmaceutici S.p.A.
      14. Joylux, Inc.
      15. Combe
      16. Reckitt
Read Less

Table 01: U.S. Vaginal Atrophy Treatment Market Revenue (USD billion) Forecast, By Therapy Type, 2021-2034

Table 02: U.S. Vaginal Atrophy Treatment Market Revenue (USD billion) Forecast, By Drug Therapies, 2021-2034

Table 03: U.S. Vaginal Atrophy Treatment Market Revenue (USD billion) Forecast, By Estrogen Based, 2021-2034

Table 04: U.S. Vaginal Atrophy Treatment Market Revenue (USD billion) Forecast, By Non-Estrogen Based, 2021-2034

Table 05: U.S. Vaginal Atrophy Treatment Market Revenue (USD billion) Forecast, By Non-Drug Therapies, 2021-2034

Table 06: U.S. Vaginal Atrophy Treatment Market Revenue (USD billion) Forecast, By Hyaluronic-Acid (HA) Based OTC Solutions, 2021-2034

Table 07: U.S. Vaginal Atrophy Treatment Market Revenue (USD billion) Forecast, By Other OTC Moisturizers & Lubricants, 2021-2034

Table 08: U.S. Vaginal Atrophy Treatment Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034

Table 09: U.S. Vaginal Atrophy Treatment Market Revenue (USD billion) Forecast, By Topical, 2021-2034

Table 10: U.S. Vaginal Atrophy Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034

U.S. Vaginal Atrophy Treatment Market
  • 2021-2034
  • 2025
  • 2021-2024
  • 135
Download Free Sample

    man icon
    Mail icon
    Captcha refresh
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann